You are here

GATC Health

Overview
Updates (29)
Comments
Contact
 

GATC Health is transforming how we diagnose and treat disease.

Imagine knowing your precise risk for Alzheimer's—or your child's risk of diabetes, decades before a potential diagnosis.

Imagine addiction cured once and for all.

Imaginelife-saving drugs developed in months, not years.

With GATC Health's AI-powered research, imagination becomes reality.

250 savvy investors have invested $15 million in the future of medicine: GATC Health.

You can too.

→ Offering Completed

 

GATC Health - A Game Changer In The Drug Development Sector

Human DNA holds the secrets to ending disease like addiction and PTSD. GATC Health is unlocking those secrets with our proprietary biotech.

Most recently, our AI-powered research has developed promising new pre-clinical molecules for PTSD, fentanyl addiction, and cocaine addiction...in mere months, not years.

The next step? In-vitro and pre-clinical testing.

→ Offering Completed

  • Discovering The Shortest Path to Better Drugs
    We believe GATC Health’s advanced AI platform creates
    safer, more effective therapeutics
    in record time.

    Offering Completed

  • GATC Health works to accelerate, optimize and
    de-risk drug discovery and development—creating
    tremendous value for our partners and customers.
    Our advanced technology closes the “AI Gap,”
    potentially saving years of R&D time and hundreds
    of millions of dollars per project.

    Offering Completed

 
Download Our Investment Presentation

What makes this technology different?

 

GATC Health’s proprietary AI simulates individual human biology to:

  • Discover new drugs or repurpose existing drugs in record time
  • De-risk drug development and clinical trials
  • Assess individual health risks
  • Recommend the best treatment options

These breakthroughs are possible with GATC Health’s patented platform, which functionally acts like a digital humanoid. Drawing on large sets of public and proprietary multiomic data, our AI simulates human biology’s billions of interactions which, we believe, leads to the following: (i) rapid and accurate target discovery, (ii) drug identification, (iii) development and (iv) validation of safety and efficacy.

At the core of our work are two proprietary assets:

Our company’s patented AI, Multiomics Advanced Technology™, or MAT.

In our opinion, MAT is unlike any other health tech AI. It is a purpose-built combination of artificial intelligence, deep machine learning and neural networks. It mimics human biology to understand diseases and treatments faster and more accurately.

An ultra-valuable multiomics biological dataset.

Genetics (DNA) provide a blueprint for what will become a human. But a 50-year-old human may differ from its “blueprint” just as a 50-year-old building differs from its original plan. Multiomics is the study of ALL the molecules in the human body involved with biological processes, including transcriptomics, proteomics, enviromics, metabolomics1. They help us understand what happens to a human over time, taking into account lifestyle, diet and environmental factors. GATC is accumulating a valuable multiomics dataset through direct data-gathering, public sources and partnerships. This multiomics dataset enables our team of leading scientists to achieve advancements in disease detection and drug discovery.

→ Offering Completed

Our Team

GATC Health is led by world-class scientists and seasoned finance professionals with over $12 billion combined funding. Prior to building GATC’s MAT platform, the firm’s experts developed some of the world’s best-known web-based technologies.

GATC Health’s leadership team intends to deliver value to shareholders and a clear path to an exit event.

Providing expert guidance to GATC’s management is the company’s Board of Advisors, which includes top researchers, medical doctors, employee benefits experts, biotech executives and government contracting experts.

 
image
John Stroh
Interim Chief Executive Officer

› 30+ years as an investment banker specializing in the health care sector

› CEO, Global Healthcare Advisors

› President & CEO, Nanospectra Biosciences

› COO, CFO & SVP, Kadmus Pharmaceuticals

› President, CEO & Director, Neomatrix LLC

 
image
Ian Jenkins
Chief Science Officer, Cofounder

› Developer of the science and process of GATC’s Predictive Multiomics™

› Co-creator of technology for Multiomics Advanced Technologies™

› Former researcher with the Human Genome Project

› VP Clinical Development, ORN Industries

 
image
Jayson Uffens
Chief Technology Officer, Cofounder

› VP Engineering, GrubHub

› Head of Engineering, Seamless

› Engineering Manager & Architect, Northrop Grumman Info Systems

› Senior Engineering Manager, GoDaddy.com

› Lead Application Architect, American Express

 
image
Preetaman Wadhwa
Chief Marketing Officer

› Global Market Lead, Oncology, Amgen

› Marketing Director, Cardiology, Amgen

› Masters Health Systems Management, Rush University

 
image
Eric Mathur
Chief Innovation Officer

› Founder of Stratagene (enabling PCR testing)

› Executive at Diversa Corp, largest biotech IPO at the time

› Recruited by Synthetic Genomics, lead researcher, purchased by Monsanto

› 50+ peer-reviewed publications and 100+ patents

 
image
Tyrone Lam
Chief Operating Officer

› Cofounder, COO, First Americans Health & Wellness

› Cofounder, COO, OneRecovery/OneHealth Solutions

› President, COO, NTN Buzztime

› VP Business Development, Predilytics

 
image
Dr. Jonathan Lakey
Chair of Scientific Advisory Board

› Professor Emeritus, Surgery and Biomedical Engineering, University of California, Irvine

› Co-inventor of the “Edmonton Protocol” islet transplantation surgery for diabetes

› 500+ authored scientific papers

› International speaker

 
image
Jeff Moses
President

› Co-founder, CMO, director of PowerOne Energy Corp

› Multiple C-level positions with growth stage companies

› Founder & creative director of ad agency serving Fortune 500 clients

 
image
Kevin Woodbridge
Executive VP

› 30+ years in finance and corporate development

› Lead $100M+ financing for various companies

 
image
Michael Manahan
Interim Chief Financial Officer

› Professor Cal State University, Dominguez Hills, Entrepreneurial Finance

› President, Match Vest Capital

› Chief Financial Officer, BluTango Inc.

 
image
Chad Penry
Director of Business Development

› Founder, Quan Financial - business consulting & strategic partnerships

› Strategic partnerships with Fortune 500 companies, leading industry professionals, celebrities, artists, athletes, and non-profit organizations.

 

GATC Health: the Future of Drug Development & Precision Medicine

Pharmaceutical R&D: Bridging the AI Gap for Drug Discovery

To our knowledge, GATC Health is the first company to bridge the AI Gap. But what is the AI Gap?

Traditionally, drug companies make assumptions about a disease and possible drug candidate molecules. This creates a giant haystack of data. They spend hundreds of millions of research dollars—and many years—analyzing each strand of “hay” trying to find the needle, or exact drug candidate.

Our competitors use AI to reduce the size of the haystack. At their best, they can reduce the haystack from 10,000 or more possible targets down to approximately 1,000. This can save several years and considerable expense—but it is only an enhancement to the traditional model.

The AI Gap is the difference between what our competitors deliver—a smaller haystack—and what GATC Health’s patented platform can deliver: the exact needle.

GATC Health skips the haystack and creates the needle.
 
 

Personalized Medicine: Genetics-Based Diagnostic Tools for Consumers

Creating new drugs starts with gathering data. Instead of paying for valuable biological data, GATC Health created a model for early disease detection and treatment optimization where customers pay us to collect their data. In turn, GATC provides a personalized, actionable report illustrating disease risk and recommended treatment options.

With a single cheek swab, our proprietary DNA test kits can identify your precise risks and recommended treatment for

  • Viral Immunity
  • Depression & Anxiety
  • Medical Cannabis
  • Health & Wellness

 

The company intends to complete the following diagnostic tools over the next 12 months:

  • Diabetes
  • Cardiac Health
  • Alzheimer’s
  • Parkinson’s
  • PTSD

 

GATC Health licenses these proprietary multiomic diagnostic tests to companies that distribute the products to consumers and physicians, enabling precision and predictive medicine across clinical settings.

New Drug Candidates in Months, Not Years

Via our relationship with Liquid Biosciences, world-class biomarker discovery company, GATC technology has created a new drug discovery platform. In our first project with Liquid Biosciences, GATC has:

  • Validated biomarkers for addiction
  • Discovered a new molecule for addiction treatment
  • We completed this work in a record breaking 9 months
  • Internal estimates of 50% or more reduction in drug discovery timeline
  • Net present value increase of over $500 million per drug, due to risk reduction, cost reduction and acceleration
  • Co-developed an AI-driven pipeline for new drug discovery, which has already produced multiple breakthrough molecules

Liquid Biosciences has completed over 192 projects with major pharmaceutical firms and research organizations for biomarker discovery, diagnostics, drug discovery, drug repurposing, database services, and analytics

 
→ Offering Completed
 
What we do

Who Benefits from GATC Health’s Technology?

In short: everyone.
Pharmaceutical companies: Our tech enables faster and more accurate drug discovery, drug repurposing and drug development. We de-risk and improve value through pre-clinical in silico and in vivo testing, prescreening clinical trial participants and validating clinical trial data.
Individuals: Patients can now access fast and affordable personalized DNA analysis of disease risk, tolerance, complications, and prevention through our distribution partners. Drugs discovered by GATC Health will be safer and more effective because they are better targeted to each disease.
Doctors: With individualized multiomic data for their patients, clinicians can provide cutting-edge, ultra-efficient medical care for better health outcomes.
→ Offering Completed

 

GATC Health Offering

Type:
Reg A + offering
 

 

→ Offering Completed

 

Mark Cuban, one of the most innovative and respected Internet-based entrepreneurs of our time, recently stated that artificial intelligence, “…will have a bigger impact on us than the Internet, than phones, mobile computing, mobile networking, wide-area networking—it’s just going to dwarf everything.” He went on to point out that, “…it’s harder to learn, harder to implement, and not everyone is going to be able to adapt…we are still in the first innings of the preseason game.”

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the world’s population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as “AI for Health,” a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.

 
The Market Opportunity

GATC Health sits at the center of four growing markets: genetic testing, AI in healthcare, personalized medicine and the world longevity economy.

Genetic Testing: $28.58 billion by 2026
Artificial Intelligence in Healthcare: $120 billion by 2028
Personalized & Precision Medicine: $493 billion and growing
World Longevity Economy: $27 Trillion in the next 5 years
Offering Completed

Press

GATC Health in the News

image
GATC Health Enters Oncology Drug Market with "Prodrugs for Cancer Treatment" Patent Application

“GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it has filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. This breakthrough, produced by the company's revolutionary Multiomics Advanced Technology™ AI platform, signals GATC Health's entrance into the oncology drug discovery market.”

-PRNewswire, April 2022
image
Artificial Intelligence That “thinks” Like Human Biology Advances Disease Detection, Treatment and Prevention

“Compared to traditional platforms that utilize artificial intelligence to accelerate mathematical, algorithmic models, GATC’S Multiomics Advanced Technology is at the forefront of a new model, where data is given biological context and value. With this distinct advantage, GATC Health provides exponentially faster, easier and more accurate results with far greater accuracy for disease detection, treatment, and therapeutics development.”

-Healthcare Business Today, May 2021
image
GATC Health: Accurate, Personalized, and Predictive Insights into Human Biology

“Initially, the time taken to analyze the multiomic data set of an individual took about 165 hours. Today, the same can be completed in under five minutes and in parallel with millions of datasets due to GATC Health’s ability to process data increasing exponentially over the years.”

- Precison Medicine, October 2021
 

Offering Completed

Competitors

As Genomics/AI companies continue to fetch huge valuations, GATC Health is uniquely positioned to flourish in these new economies. Our proprietary MAT AI/genomics platform and Predictive Multiomics database are proven to deliver groundbreaking results across a variety of lucrative applications advancing human health and scientific progress.

GATC Health’s Competitive Advantage

  • MAT AI provides superior biological context to omics data with the faster processing speed and scalability preferred by major industry partners.

  • The opportunity is immense. GATC’s technology can be taught to address nearly any condition, disease or disorder.

  • Our Predictive Multiomics database and MAT AI make us a complementary technology to others in this space. Companies that may have been competitors can now utilize our technology as partners.
Biological Context
Faster Processing Speed
Scalability

Participate in the Future of Biotech With GATC Health

As the industry continues to push for expedited solutions for Emergency Use Authorizations, drug discovery, biomarker discovery, precision medicine, and more, GATC Health will continue to lead and innovate.

 

It’s an exciting time to be in biotech.

As a GATC Health investor, you’re in the perfect place at the perfect time. Will you step into the future with us?

Offering Completed

Advisory Board

 
image
Dr. Stanley Lewis
Technology Advisor

› Co-Founder and CEO A28 Therapeutics

› 20+ year biotechnology executive. Dr Lewis is the former CMO at TaiMed Biologics (public), Ansun Biopharma (private). Diabetes Relief (private) and Dir. of Drug Development at Tanox (sold to Genentech)

› Developed TROGARZO(TM) from Phase 1 to FDA approval

 
image
Dr. Jack Lewin
Technology Advisor

› Principal and Founder Lewin and Associates LLC

› Chairman, National Coalition on Health Care, Washington DC

› Former President and CEO of Cardiovascular Research Foundation

 
image
Dr. Jonathan Lakey
Science Advisor

› Professor Emeritus, Surgery and Biomedical Engineering

› University of California Irvine

 
image
Mark Palaima
Technology Advisor

› eBay—Chief Architect, Fellow—10 yrs.

› Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder

› Ismintis Systems —Founder

 
image
Patrick Lilley
Science Advisor

› CEO and Founder, Liquid Biosciences

› Inventor of over 75 trade secrets and patents

› Co-Chair Blockchain and AI Task Force

› Board Member, Mamogen, HepGene, LiquidLung

 
image
Dr. Chad Beyer
Science Advisor

› PhD, MBA, 25 years of CNS drug discovery and development experience

› 33 INDs; 70+ manuscripts; 2 blockbuster medications

› NIDA; Wyeth; Ariel and Promentis Pharmaceuticals

› Entrepreneur in Residence, Lafayette College

 
image
Dr. Chitra Bhakta
Science Advisor

› Chronic disease specialist

› Physician at OC Integrative Medical Center

 
image
Dr. Negar Motoyagheni
Science Advisor

› Anesthesiology and Intensive Care TUMS/SBU, Scientist UCLA

› Regenerative Medicine Fellowship WFIRM

› 20+ academic certificates

 
image
Dr. David Kushner
Science Advisor

› 35+ years as Nuclear Radiology Specialist / US Navy Physician

› Fellow in Musculoskeletal imaging and Nuclear Medicine

› Assistant professor at Uniform University of the Health Science

Business Advisors

 
image
Steve Lebedoff
Business Advisory Board Member

› President, BeneTrax, an Aon company (Global Risk and Benefit Consulting)

› Strategic Director, National Accounts (Fortune 500) Aon Worksite Solutions

› Executive Officer, PPN Health Access

› Co-founder, Center for Sustainable Healthcare, University of Nevada

 
image
Jim Arellano
Business Advisory Board Member

› President and Founder BP Insurance

› Former VP of National Accounts, United Health Group

› 35+ years’ experience in Healthcare Industry

 
image
Darius Naigamwalla
Business Advisory Board Member

› Executive Vice President, Two Labs Pharmaceutical

› Former CEO, CEEK Enterprises: BioPharma Consulting

› Former President, Campbell Alliance (now Syneos Health)

› 20+ years in BioPharma consulting & commercialization

 
image
LTC (R) Wade Jost
Military + Federal Advisor

› CEO, 640 Areas (Service-Disabled Veteran Owned Small Business

› U.S Army’s Rapid Equipping Forces (REF)

› Office of Secretary of Defense Joint IED Defeat organization

› U.S Military Academy of West Point

 

Offering Completed

Copyright © 2022 · GATC Health

Gatchealth

Gatch Health

Getc health

Gathealth

Get health

Updates

April 19
GATC Health Licenses Diabetes Platform to GATC DB Care Corp

GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that it has granted an exclusive license for its diabetes platform to GATC DB Care Corp. GATC DB Care was formed specifically to continue development and productization of the GATC Health diabetes platform under the direction of renowned diabetes researcher, Dr. Jonathan Lakey, co-inventor of the Edmonton Protocol for pancreatic islet transplantation and Professor of Surgery and Biomedical Engineering, Director, Clinical Islet Program at University of California Irvine. “I am truly excited to work with the GATC team to integrate their novel platform technology for both Type 1 and 2 diabetes, developing important predictive signals that we can use to help all those that suffer from diabetes, says Dr Lakey. “The formation of GATC DB Care and subsequent licensing of our diabetes platform is illustrative of how GATC Health goes to market in a new vertical,” explained John Stroh, interim CEO of GATC Health. “By licensing this new technology to GATC DB Care, we are allowing this platform to reach its full valuation potential in the US diabetes market, which accounted for $237 billion in direct medical costs in 2017, according to the American Diabetes Association. In fact, the CDC claims that $1 out of every $4 spent on health care in the US goes towards caring for diabetes patients.” GATC DB Care is devoted to improving diabetes detection and treatment by utilizing GATC Health’s proprietary Multiomics Advanced Technology™ (MAT). This diabetes-specific instance of this technology will help the company deliver on three goals: First, unlocking the genomic and environmental triggers for type 1 and type 2 diabetes so that targeted interventions can stop the diseases before they start. Second, to provide patients and their clinicians with precision prognostics to accurately predict disease-related outcomes. Third, to greatly accelerate drug discovery and treatment validation, providing actionable direction in record time and with unmatched accuracy for therapeutics development partners. As the exclusive licensee of GATC Health’s diabetes technology, GATC DB Care management has the autonomy to seek its own financing, retain leading research and development experts, attract research, drug and device partners, and eventually seek its own exit through acquisition, merger or IPO.”

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

March 23
Dr. Jonathan Lakey to Head Development Team to Further GATC Health’s Diabetes Diagnoses and Treatment Platform

GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that Dr. Jonathan Lakey, co-developer of the Edmonton Protocol and world-renown diabetes and islet transplantation expert, has joined the company’s board of advisors. Dr. Lakey’s input and guidance will be integral to the development of GATC Health’s diabetes platform, which combines multiomic analyses with advanced machine learning to aid early detection, intervention and treatment of diabetes and diabetes therapies including islet and stem cell transplantation.

“Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in diabetes,” noted GATC’s interim CEO, John Stroh. Dr. Lakey is the recipient of numerous national awards in the field of diabetes and islet transplantation. He has served on scientific advisory boards for several diabetes biotechnology companies, on regulatory boards establishing safety standards for cell and tissue transplantation, and on editorial boards of diabetes, biomaterial and transplantation journals. We are honored to welcome him to our advisory board and look forward to his support in the development of our diabetes platform.”

Dr. Lakey received his doctorate degree from the University of Alberta, Canada and pursued his postdoctoral training in the Indianapolis and Seattle before returning to establish his research program at the University of Alberta. Dr. Lakey was also the Director of the Comprehensive Tissue Bank in Edmonton. His contributions and partnership with Dr. James Shapiro led towards the improvement of islet isolation techniques and the development of the Edmonton Protocol for patients with Type I diabetes, a recognized major advancement in the treatment of Type 1 diabetes. Currently, Dr. Lakey is currently a Professor of Surgery and Biomedical Engineering and the Director of the Clinical Islet Program at the University of California Irvine.

“GATC Health has presented me with an incredible opportunity to make significant advancements in the detection and treatment of diabetes,” stated Dr. Lakey. “I have been tasked with assembling a world-class team of scientific and technical experts to further develop a diabetes-focused platform utilizing the company’s Multiomics Advanced Technology™ (MAT). The GATC Health diabetes platform has the potential to revolutionize the way we detect diabetes before it develops in an individual and possibly arrest its progression through new treatments and transplantation protocols.”

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

March 04
Cannaponics to Provide GATC Health’s Medical Cannabis Testing Platform to Patients & Physicians Throughout Australia

GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that its Medical Cannabis platform licensee, GATC Canna, has entered into an agreement with Cannaponics, an integrated medicinal cannabis company based in Australia. The agreement allows Cannaponics to offer GATC Health’s genetics-based medical cannabis test to physicians and their patients. By analyzing an individual’s genetic response to medical cannabis with GATC Health’s testing platform, Cannaponics will provide medical professionals with the specific data necessary to develop personalized medical cannabis treatment plans, as well as assess their efficacy over time.

Cannaponics is a fully integrated Australian Medicinal Cannabis company based in Western Australia, with sites in Perth and Collie. Cannaponics was awarded a grant from the government’s Collie Futures Industry Development Fund to acquire and develop 160 acres of prime agricultural land in the South West of Western Australia. This is Cannaponics’ Cannabis Hemp hub, which will include a world class facility for the cultivation, research and production of cannabis and hemp, including a 72,000sqm greenhouse and a cutting-edge cannabis research and development facility. The facility is expected to create up to 1,000 new jobs over the next five years. Construction will begin this year with the first harvest to happen in early 2021, followed by a proposed initial public offering (IPO) and listing on the Australian Stock Exchange.

“The medical cannabis industry is an under-served and under-utilized field with significant potential to improve lives,” said John Stroh, Interim CEO, GATC Health. “We are looking forward to working with Cannaponics to provide patients and physicians with accurate information that could expand the use of medicinal cannabis and improve results of treatment for patients.”

Cannaponics will offer GATC Health’s Medical Cannabis DNA test kit in specialist clinics, as well as via a direct-to-consumer online platform. GATC Health’s Medical Cannabis platform can analyze up to 6.4 billion data points, and utilizes a unique combination of genetic testing, AI, machine learning and Predictive Multiomics™. This analysis is summarized in a personalized, actionable report that addresses the use of medical cannabis for anxiety, pain relief and sleep quality. It includes precision dosing guidelines, THC/CBD ratios, CBN and CBG cannabinoid benefits, strain and terpene recommendations, and potential drug interactions.

“Cannaponics is focused on delivering high-quality products and improving access to patients in need,” said Dr. Stephen Chalk MA MBBS FRACGP, Medical Director of Cannaponics. “This partnership will allow us to advance the work that we are doing in medical cannabis and provide accurate, personalized recommendations to our customers.” Cannaponics are in consultation with the Therapeutics Goods Administration to ensure full compliance with legislation governing In-vitro Diagnostic Testing.

 

About Cannaponics

Cannaponics is a Western Australian based fully integrated Medicinal Cannabis company. Cannaponics owns a 160-acre site in Collie, WA, with developments including a 10,000 square foot Greenhouse, Headhouse and Manufacture facility. Cannaponics has secured $2 million backing from the state government, representing the largest government grant ever provided to a Cannabis company in Australia. Cannaponics aims to be the first carbon-neutral Cannabis company, with off-grid power provided by onsite solar farm. Cannaponics is developing propriety delivery technology to enhance the absorption profiles of locally manufactured Cannabis medications.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

December 23
GATC Health Corp Announces Completion of World’s First Viral Immunity Platform

GATC Health Corp, developer of Predictive Multiomics™, announces the completion of its Viral Immunity platform. This platform analyzes an individual’s whole genome to determine immune response, infection tolerance and possible health complications from viral infection. This platform is customized to evaluate health risks for the most virulent and dangerous viruses at any point in time.

“The Viral Immunity platform is a digital neural network operating in conjunction with the company’s powerful Multiomics Advanced Technology™ or MAT. MAT analyzes genomic data as well as other biological datasets (multiomics) to allow accurate predictions regarding outcomes to specific health risks,” stated Jayson Uffens, GATC Health’s director of technology. “We believe this is the first platform of its kind to determine an individual’s exact risk of exposure to viruses such as H1N1, Ebola and SARS-CV-2.”

Currently, the platform is in the early stages of beta testing. It is expected that the company will announce a licensing agreement for the Viral Immunology platform in the near future.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

September 15
GATC Health Welcomes Genomics Expert Eric J. Mathur to its Board of Advisors

Biotechnologist, genomics expert and successful entrepreneur Eric J. Mathur has accepted a position on GATC Health’s Board of Advisors. As a GATC Advisor, Mr. Mathur will work with the company’s science, technology and management teams to review and optimize product development, introduce scientific, medical, manufacturing and marketing resources to the company and help identify strategic relationships.

“I’ve known Eric for some time and am extremely pleased to welcome him to our advisory board,” stated John Stroh, the company’s CEO. “It is a testament to the value of our technology and vision of our leadership that we can attract scientists such as Eric, who are at the very pinnacle of their fields. Eric understands the magnitude of what we are trying to achieve and will be instrumental in helping us reach our goals.”

Mr. Mathur’s career spans 40 years in basic and applied biotechnology with a focus on translational science. His expertise encompasses molecular biology, genome sciences, environmental microbiology, molecular diagnostics and high throughput drug discovery. A serial entrepreneur in the early San Diego biotech industry, Mr. Mathur participated in the formation of several start-ups including Stratagene Cloning Systems (acquired by Agilent); Diversa Corporation (acquired by BASF & British Petroleum,) and Synthetic Genomics (spinout Agradis acquired by Monsanto), among others. He is an internationally recognized speaker and accomplished biotechnologist with 50+ peer reviewed publications and over 100 issued patents.

“My passion lies in leveraging genomics, biologics and polymer technologies to develop sciencedriven nutraceuticals, plant-based-medicines and modern therapeutics,” Noted Mr. Mathur. “This aligns perfectly with GATC Health’s mission to discover new and beneficial ways to improve health and wellness through DNA analysis. I am very pleased to join this very capable team and believe its products and services are perfectly positioned for the next generation of medicine."

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

  •  

Comments

Post comment

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN EVENTUAL OFFERING OF ITS SECURITIES. THE COMPANY IS NOT UNDER ANY OBLIGATION TO MAKE AN OFFERING UNDER REGULATION A. IT MAY CHOOSE TO MAKE AN OFFERING TO SOME, BUT NOT ALL, OF THE PEOPLE WHO INDICATE AN INTEREST IN INVESTING, AND THAT OFFERING MIGHT NOT BE MADE UNDER REGULATION A. IF THE COMPANY DOES GO AHEAD WITH AN OFFERING, IT WILL ONLY BE ABLE TO MAKE SALES AFTER IT HAS FILED AN OFFERING STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND THE SEC HAS “QUALIFIED” THE OFFERING STATEMENT. THE INFORMATION IN THAT OFFERING STATEMENT WILL BE MORE COMPLETE THAN THE INFORMATION THE COMPANY IS PROVIDING NOW, AND COULD DIFFER IN IMPORTANT WAYS. YOU MUST READ THE DOCUMENTS FILED WITH THE SEC BEFORE INVESTING.